CompletedNCT01346163
PF-03654746 Added to Schizophrenia Treatment and Thinking Skills
About this title
Read the official source —Medication studyAges 18–40United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 40 years. Other eligibility criteria applied.
- Listed locations
- PhiladelphiaSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateApril 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- University of Pennsylvania
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT01346163
- Official title
Show the full official title
A Phase1B Study: A Placebo Controlled Study of PF-03654746 Given as Add-On Treatment of Cognitive Deficits in Schizophrenia
Get this study by email
Recruitment & locations
CompletedPhiladelphia
Questions about this study
Who is behind this study?
The study sponsor is University of Pennsylvania, a university.
Did this study involve medication?
Yes. The study involved medication, including PF 03654746.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 40 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia